Dr. Heba Ismail, MD

Dr. Ismail practices at California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD in San Francisco, California.

Dr. Ismail's NPI, 1124296124, was assigned on February 13, 2008. Dr. Ismail graduated from University of Alexandria Faculty of Medicine in 2001. Dr. Ismail's California license number on file is A102593.

Dr. Ismail's primary practice is California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD, at 2333 Buchanan St, San Francisco, CA 94115.

Dr. Ismail's primary practice is California Pacific Medical Center - B.H. Cancer Care Center-Buchanan St - HOPD in San Francisco, California. Dr. Ismail is also affiliated with California Pacific Medical Center Van Ness Campus. The medical group on file is Palo Alto Foundation Medical Group. Dmand AI also links Dr. Ismail to 3 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ismail practices, 8 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Ismail's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Ismail is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Ismail's licenses on file in 2 states: California and Missouri.

CMS data shows 548 Medicare services from Dr. Ismail across 9 procedure codes in 2024, for 329 Medicare patients. Medicare paid $74,700 for them.

CMS counts 329 Medicare patients who saw Dr. Ismail in 2024. The largest group is 65 to 74, with 138 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 44% are also on Medicaid. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ismail's median patient age at 70, with 47% women.

In 2024, Dr. Ismail wrote 53 Medicare Part D claims for 19 patients. 36% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $10,159 in total drug cost. In 2023, CMS named 22 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Ismail for performance year 2024, reported as part of a group. Dr. Ismail accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ismail as offering telehealth.

Dmand AI links 14 papers to Dr. Ismail, published from 2015 to 2025. 2025 was the busiest year, with 6. The most frequent topics are Diabetes Mellitus, Type 1, Autoantibodies and Blood Glucose. Dr. Ismail has published most often in Diabetologia. Dr. Ismail's most frequent co-authors are Laura M. Jacobsen, MD, Maria Jose Redondo, MD and Emily Kristen Sims, MD.

CMS Open Payments shows 200 general payments to Dr. Ismail from 35 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 37% of the total. Gilead Sciences, Inc. paid the most, $7,179.

Dr. Ismail graduated from University of Alexandria Faculty of Medicine in 2001.

Dr. Ismail is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.